Abstract
Fucoidans -- sulphated polysaccharides extracted from brown algae – could be beneficial in patients with ischemic diseases. Their antithrombotic and proangiogenic properties promote in animals, neovascularization and angiogenesis which prevent necrosis of ischemic tissue. In 1997, endothelial progenitor cells were first identified in human peripheral blood. They are recruited from bone marrow and contribute to neovascularization after ischemic injury. Mobilization of these cells in ischemic sites is an important step in new vessel formation. It is thought that the progenitors interact with endothelial cells, then extravasate and reach ischemic sites, where they proliferate and differentiate into new blood vessels. Although chemokines, cytokines and adhesion molecules are thought to be involved, the precise mechanism of progenitor mobilization is not fully understood. Recent studies suggest that stromal-derived factor 1 plays a critical role at several steps of progenitor mobilization. Given the role of proteoglycans within bone marrow, at the endothelium surface, and in growth factor and chemokine binding, fucoidans might influence the mobilization of endothelial progenitor cells and their incorporation in ischemic tissue. This review provides an update on circulating endothelial progenitors and their role in neovascularization. It focuses on recent advances in our understanding of interactions between these progenitor cells and exogenous sulphated polysaccharides, and their implications for understanding the fucoidan mechanism of action.
Keywords: Fucoidan, sulphated polysaccharides, endothelial progenitor cells, neovascularization, angiogenesis, cytokines, growth factors
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Neoangiogenesis Induced by Progenitor Endothelial Cells: Effect of Fucoidan from Marine Algae
Volume: 5 Issue: 1
Author(s): C. Boisson-Vidal, F. Zemani, G. Caligiuri, I. Galy-Fauroux, S. Colliec-Jouault, D. Helley and A.-M. Fischer
Affiliation:
Keywords: Fucoidan, sulphated polysaccharides, endothelial progenitor cells, neovascularization, angiogenesis, cytokines, growth factors
Abstract: Fucoidans -- sulphated polysaccharides extracted from brown algae – could be beneficial in patients with ischemic diseases. Their antithrombotic and proangiogenic properties promote in animals, neovascularization and angiogenesis which prevent necrosis of ischemic tissue. In 1997, endothelial progenitor cells were first identified in human peripheral blood. They are recruited from bone marrow and contribute to neovascularization after ischemic injury. Mobilization of these cells in ischemic sites is an important step in new vessel formation. It is thought that the progenitors interact with endothelial cells, then extravasate and reach ischemic sites, where they proliferate and differentiate into new blood vessels. Although chemokines, cytokines and adhesion molecules are thought to be involved, the precise mechanism of progenitor mobilization is not fully understood. Recent studies suggest that stromal-derived factor 1 plays a critical role at several steps of progenitor mobilization. Given the role of proteoglycans within bone marrow, at the endothelium surface, and in growth factor and chemokine binding, fucoidans might influence the mobilization of endothelial progenitor cells and their incorporation in ischemic tissue. This review provides an update on circulating endothelial progenitors and their role in neovascularization. It focuses on recent advances in our understanding of interactions between these progenitor cells and exogenous sulphated polysaccharides, and their implications for understanding the fucoidan mechanism of action.
Export Options
About this article
Cite this article as:
Boisson-Vidal C., Zemani F., Caligiuri G., Galy-Fauroux I., Colliec-Jouault S., Helley D. and Fischer A.-M., Neoangiogenesis Induced by Progenitor Endothelial Cells: Effect of Fucoidan from Marine Algae, Cardiovascular & Hematological Agents in Medicinal Chemistry 2007; 5 (1) . https://dx.doi.org/10.2174/187152507779315778
DOI https://dx.doi.org/10.2174/187152507779315778 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardioprotective Effects of Serca2a Overexpression Against Ischemiareperfusion- induced Injuries in Rats
Current Gene Therapy New-Onset Hyperglycemia and Acute Coronary Syndrome: A Systematic Overview and Meta-Analysis
Current Diabetes Reviews Transport of Nucleoside Analogs Across the Plasma Membrane: A Clue to Understanding Drug-Induced Cytotoxicity
Current Drug Metabolism Exercise as Treatment for Neuropathy in the Setting of Diabetes and Prediabetic Metabolic Syndrome: A Review of Animal Models and Human Trials
Current Diabetes Reviews Fetuin-A: A Multifunctional Protein
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Silent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease
Current Hypertension Reviews Mediterranean Diet and Low-grade Subclinical Inflammation: The Moli-sani Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetically Engineered Stem Cells for Therapeutic Gene Delivery
Current Gene Therapy Cardiovascular Magnetic Resonance T2-weighted Imaging of Myocardial Edema in Acute Myocardial Infarction
Recent Patents on Cardiovascular Drug Discovery Interatrial Block in the Modern Era
Current Cardiology Reviews Targeting Vascular Niche by Parathyroid Hormone
Current Medicinal Chemistry New Insight in Antiplatelet Therapy Monitoring in Cardiovascular Patients: From Aspirin to Thienopyridine
Cardiovascular & Hematological Disorders-Drug Targets Complement and Complement Regulatory Proteins as Potential Molecular Targets for Vascular Diseases
Current Pharmaceutical Design Targeting NO/cGMP Signaling in the CNS for Neurodegeneration and Alzheimer’s Disease
Current Medicinal Chemistry Microvasculature Recovery by Angiogenesis After Myocardial Infarction
Current Pharmaceutical Design Therapeutic Potential of Endothelial Progenitor Cells for Cardiovascular Diseases
Current Vascular Pharmacology Pigment Epithelium-Derived Factor: A Novel Therapeutic Target for Cardiometabolic Diseases and Related Complications
Current Medicinal Chemistry Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches
Current Pharmaceutical Biotechnology Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
Current Medicinal Chemistry Proteomic Analysis of the Kidney in Rat Biliary Cirrhosis
Current Proteomics